Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Cheng-Hong Tsai, MD MSc, Feng Ming Tien, MD MSc, Hsin-An Hou, MD PhD, Jia-Hau Liu, MD, Shang-Ju Wu, MD PhD, Yu-Wen Wang, MSc., Chien-Chin Lin, MD, Bor-Sheng Ko, MD PhD, Wen-Chien Chou, MD PhD, Yun-Chu Lin, MD, Chieh-Lung Cheng, MD, Li-Chun Lu, MD PhD, Sung-Hsin Kuo, MD PhD, Ruey-Long Hong, MD PhD, Tai-Chung Huang, MD PhD, Ming Yao, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138481

Published: 2020

Journal Articles

Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy

Cheng-Hong Tsai, MD MSc, Jih-Luh Tang, MD, PhD, Feng-Ming Tien, MD, M.Sc, Yuan-Yeh Kuo, PhD, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Yen-Ling Peng, M.Sc., Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, PhD, Wen-Chien Chou, MD, PhD, Chien-Yu Chen, PhD, Hsin-An Hou, Hwei-Fang Tien, MD, PhD

Blood (2019) 134 (Supplement_1): 2698.

https://doi.org/10.1182/blood-2019-126870

Published: 2019

Journal Articles

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Chao-Hung Wei, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD, PhD, Yuan-Yeh Kuo, PhD, Feng-Ming Tien, MD, M.Sc, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Yen-Ling Peng, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, MD, Liang-In Lin, PhD, Wen-Chien Chou, MD, PhD, Chien-Yu Chen, PhD, Hsin-An Hou, Hwei-Fang Tien, MD, PhD

Blood (2019) 134 (Supplement_1): 2705.

https://doi.org/10.1182/blood-2019-124657

Published: 2019

Journal Articles

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

Shaun Fleming, MBBS,, Cheng-Hong Tsai, MD MSc, Hartmut Döhner, MD, Konstanze Döhner, Elli Papaemmanuil, PhD, Hwei-Fang Tien, MD, PhD, John Reynolds, PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Hsin-An Hou

Blood (2019) 134 (Supplement_1): 1392.

https://doi.org/10.1182/blood-2019-128243

Published: 2019

Journal Articles

A Leukemic Stem Cell Signature-Based Scoring System for Predicting Prognosis in Myelodysplastic Syndrome Patients

Yu-Hung Wang, MD, Chien-Chin Lin, MD, Chi-Yuan Yao, MD, Cheng-Hong Tsai, MD, M.Sc., Hsin-An Hou, MD PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2018) 132 (Supplement 1): 1810.

https://doi.org/10.1182/blood-2018-99-110768

Published: 2018

Journal Articles

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

Blood (2018) 132 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2018-99-114315

Published: 2018

Journal Articles

Metabolic Alterations May Contribute to Cabozantinib Resistance in Acute Myeloid Leukemia Cells with FLT3 -ITD

Fang-Yu Lo, Kit Man Ng, MS, Wen-Chun Chen, MS, Chung-Yi Hu, PhD, Hsin-An Hou, MD PhD, Cheng-Hong Tsai, MD, M.Sc., Da-Liang Ou, PhD, Hwei-Fang Tien, MD, PhD, Liang-In Lin, PhD

Blood (2018) 132 (Supplement 1): 2785.

https://doi.org/10.1182/blood-2018-99-118322

Published: 2018

Journal Articles

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Jui-Che Chen, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hsin-An Hou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 1300.

https://doi.org/10.1182/blood.V130.Suppl_1.1300.1300

Published: 2017

Journal Articles

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, M.Sc., Hsin-An Hou, MD, PhD, Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Yu-Chiao Chiu, PhD, Chien-Chin Lin, MD, Liang-In Lin, PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 2582.

https://doi.org/10.1182/blood.V130.Suppl_1.2582.2582

Published: 2017

Journal Articles

Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, Hsin-An Hou, MD PhD, Wen-Chien Chou, MD PhD, Chien-Chin Lin, MD, Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, Bor-Sheng Ko, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2015) 126 (23): 4956.

https://doi.org/10.1182/blood.V126.23.4956.4956

Published: 2015

Journal Articles

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, Hwei-Fang Tien, MD PhD, Hsin-An Hou, MD PhD, Wen-Chien Chou, MD PhD, Yan-Jun Lai, Yuan-Yeh Kuo, PhD, Chien-Yuan Chen, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Shang-Yi Huang, Bor-Sheng Ko, MD PhD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Yao-Chang Chen, MDPhD, Mei-Hsuan Tseng, Chi-Fei Huang

Blood (2014) 124 (21): 1034.

https://doi.org/10.1182/blood.V124.21.1034.1034

Published: 2014

NARROW

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Minimal Residual Disease Monitoring By Next-Generation Sequencing in Patients with Acute Myeloid Leukemia: MRD Positivity after First Consolidation Chemotherapy Can Better Predict Clinical Outcomes Than That after Induction Chemotherapy

The Clinical Association and Prognostic Impact of IL1RAP Expression in Patients with De Novo Acute Myeloid Leukemia

Use of Machine Learning in 2074 Cases of Acute Myeloid Leukemia for Genetic Risk Profiling

A Leukemic Stem Cell Signature-Based Scoring System for Predicting Prognosis in Myelodysplastic Syndrome Patients

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

Metabolic Alterations May Contribute to Cabozantinib Resistance in Acute Myeloid Leukemia Cells with FLT3 -ITD

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

Genetic Alterations and Their Clinical Implications in Older Patients with Acute Myeloid Leukemia

Higher Expression of Suppressor of Cytokine Signaling1 ( SOCS1 ) in the Bone Marrow Is an Unfavorable Prognostic Factor in Adult Patients with De Novo Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only